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Chronic lymphocytic leukaemia (CLL) in Central Africans
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*E M MBVUNDULA, *E D MAGOMBO, *H N MALATA
Abstract
Objective: To document the clinical and haematological features of chronic lymphocytic leukaemia (CLL) 
in Central Africans.
Design : Prospective descriptive analysis.
Setting : Tertiary referral teaching hospitals.
Subjects: 48 Zimbabweans and 27 Malawians formed the basis of this analysis.
Results: There were 75 patients (40 males and 35 females) studied and their ages ranged from 32 to 78 years 
with a mean ± s.d. o f 56.8 ±10.1 years. The peak age incidence of 26.7% occurred between 60 to 64 year old 
and 21.3% were below  50,years. The major clinical findings included: splenomegaly (68%); hepatomegaly 
(37.3%); anaemia (34.7%); lymphadenopathy (33.3%) and nine (12%) patients were diagnosed-incidentally. 
The majority o f patients (78.7% ) had Rai stage III and IV and only seven (9.3%) patients were in stage 0. O f 
the 32 patients treated with chemotherapy, 25.9% and 59.3% achieved complete or partial remissions 
respectively. Six patients were still alive after a follow  up period of a mean ± s.d o f 39.3 ± 24.4 months; five  
were lost to follow  up after a mean ± s.d period o f 28.6 ± 18.8 months and 16 were dead after a mean ± s.d. 
period of 25.7 ± 19.1 months. The main causes of death in the treated group were septicaemia in sixjpneumonia  
in four and tuberculosis in three. In the untreated group of 43 patients, two refused therapy, four died shortly 
after diagnosis and 37 were lost to follow  up, /
Conclusions and recommendations: Although the study has disclosed that CLL is not rare in central Africans 
and its presentations are similar to cases reported in the literature, the majority of patients seek  medical 
treatment late. Optimal therapy is impossible due to lack of chemotherapy and supportive services.Therefore, 
it is recommended that tertiary referral centers in African health systems should be equipped for better 
management o f CLL patients.,
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----  Introduction
Chronic lymphocytic leukaemia (CLL) is a haematological 
malignancy characterized by monoclonal proliferation 
and accumulation of mature looking small lymphocytes 
particularly in the'marrow, blood, lymph nodes and spleen.1-3 
In 90 to 95% of cases, the cells are monoclonal B 
lymphocytes.3 Although in Europe and America CLL of 
B-cell origin is the commonest type of leukaemia, it is 
extremely rare before the age of 50 years, after which its 
incidence increases progressively with age. The male to 
female (M:F) ratio is 2 :l.2,3 In contradistinction to these 
findings, CLL is rare throughout Southern, South Eastern
and Eastern Asia as well as in Asians who;, migrated to 
North: America and Europe. This suggests genetic 
determinants as they usually suffer from the CLL of T-cell 
origin: 7  7
Reports from sub-Saharan Africa4 show that CLL occurs 
from the age of 17 years with the overall M;F ratio of 1:1. 
There is a bimodal distribution so that about half of . the 
patients are aged 45 years or less with a M:F ratio of 1:2. 
Over 45 years the M:F ratio is 2:1, as in the developed 
western world. Frequency rises in women towards the end 
of thefir reproductive life. CLL is associated with upper 
socio-economic status and with rural habitation.4,5
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Previous studies from Zimbabwe6 and Malawi7 show 
that CLL is not rare in indigenous Central Africans. 
However, these studies were not detailed with respect to 
CLL and cell marker studies were not attempted. This 
study presents a detailed description of the clinical, 
haematological, immunophenotyping, treatment and follow 
up results and compares With experience from Africa and 
elsewhere in the world.
M aterials and M ethods
The study comprised 48 Zimbabweans and 27 Malawians 
who were consecutively seen and prospectively documented 
by the authors at the Departments of Haematology of the 
University of Zimbabwe Medical School, Harare, 
Zimbabwe, from January 1986 to June 1989 and at the 
University of Malawi, College of Medicine, Blantyre, 
Malawi between January 1997 to December 2002 
respectively. For each patient, clinical details were recorded 
after a history and a physical examination had been 
performed. \
In Harare, full blood counts (FBCs) were determined 
using Coulter Counter Models S and JS and in Blantyre, 
FBCs were analyzed using the Coulter Counter Onyx. 
Other diagnostic tests done were peripheral blood films 
and bone marrow aspirations which were stained according 
to standard techniques.8 Other relevant tests which were 
carried out on some of the patients in order to conserve 
expensive reagents included antiglobulin (Coombs) test; 
serum protein electrophoresis and estimation of gamma 
globulins; immunophenotyping using Flow cytometer 
Model FACScan, Becton Dickinson, USA. The diagnosis 
of CLL was based on clinical and haematological findings 
viz: persistent lymphocytosis a 10.0 x 109/1 with or without 
bone marrow lymphocyte count a 30% of marrow cells.2’9 
The clinical staging was according to Rai, et al.10 The 
indications for therapy were Rai stages III, IV or bulky and 
symptomatic stages I or II disease.9
Chlorambucil 0.1 to 0.2mgs/kg/day or cyclophosphamide 
2 to 3 mgs/kg/day with or without prednisolone 40 to 60 
mgs/m2/day were administered and treatment was given 
for at least five months before evaluating response. 
Response criteria were as described by Sawitsky, et al.n 
These were complete remission\(CR) = normalization of 
all clinical and haematological parameters; partial remission 
(PR) = reduction in the size of organomegaly to 50% of that 
at diagnosis and lymphocyte count less than 15.0 x 1071; 
no response (NR) = no change in the clinical or lymphocyte 
count; progression (Pg) = worsening over 28 days with 
increase in size of organs and lymphocyte count. Due to 
scarcity of chemotherapeutic agents, the majority ofpatients 
were treated conservatively and followed up in the clinic 
with observation only. The results were analyzed using the 
desk-top Scientific Calculator Model HP48GX, Texas 
Instruments, USA. The student’s t-test and Chi squared 
tests were used to determine statistical significance between 
groups. A p value of less than 0.05 was considered 
significant.
R esults
Of the 75 patients studied, 40 were males and 35 females, 
giving an overall M:F ratio of 1.1:1. Their ages ranged 
from 32 to 78 years with a mean ±s.d. of 56.8 ± 10.1 years. 
Table I shows the age and sex distribution of the CLL 
patients in the study. In 16 (21.3%) patients, CLL occurred 
below the age of 50 years. Of these 16 patients, 10 (62.5%) 
were women of a relatively younger age. The clinical 
presentation at diagnosis is shown in Table II.
Table I: Age and sex distribution of 75 CLL patients.
Sex Total
Age group (yrs) Male Female No. %
SO-34 ' . 2 .  . - ' ^ 2  \  2.7
35-39 3 \  5.3
40-44 1 .— ' " - r s iTV 4 ^ 5.3
45-49 (  r c. 6 . \  8.0
50-54 n , f T \  7 . 9 ° °  1 1 ^ - - ,  14.7
55-59 \  3 \ t  u 7 \  13’3
60-64 \  12 -  26.7
65-69 ^ 6 ' - ' " "  _______ _ 17.3 .
70-74 r ' At O vC,P\ - - - - - ' - 2 ' ' ^  3 4.0
a 75 \ " 7 , , 2 - " ^ ^  - 2 2.7
Total 40 35 75100.0
Table II: Presenting clinical features in 75 CLL patients.
Clinical feature
No.
(n = 75) %
Symptoms:
Splenic discomfort/pain 33 44.0
Weakness/fatigue/malaise/syndrome 25 33.3
Abdominal fullness or mass 18 24.0
Weight loss 16 21.3
Fevers on and off 8 10.7
Bleeding tendency 2 2.7
Headaches 2 2.7
Excessive sweating 2 2.7
Signs:
Spleen palpable 51 68.0
1-9cms (mild to moderate splenomegaly) 30 40.0
10-19.9 cms (severe splenomegaly) 19 25.3
£ 20cms (gross splenomegaly) 2 2.7
Spleen not palpable 7 9.3
Hepatomegaly 28 37.3
Anaemia/pallor 26 34.7
Lymphadenopathy (cervical/axillary/inguinal). 25 33.3
Pyrexia 8 10.7
Cardiac failure 3 4.0
Respiratory tract infections 2 2.7
Incidental diagnosis 9 12.0
C lin ica l fe a tu r e s : Com plaints attributable to 
splenomegaly (68%) and constitutional symptoms were 
the dominant clinical features and accounted for 68% and 
65.3% respectively, followed by hepatomegaly 37.3%, 
anaemia 34.7%, lymphadenopathy in 33.3%, pyrexia 
10.7%, cardiac failure 4% and other features 10.8%. In 
nine (12%) patients, the diagnosis was incidental, i.e.
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patients were being investigated for unrelated complaints, 
blood donation or for employment purposes.
Table I I I : Haematological findings at diagnosis in- 75 CLL 
patients.
Blood count index N o , . . % . . . Mean ± s.d . Range
Wbc (x 109/1) 7 5 ' . 100.0 ; 127.0 ± 128.0 15.2-675.0
Hb (g/dl) 75 ' 100.0 : ■ 9.5 ± 2.5 3.3-15.2 ■
Platelets (x 109/1) 75 100.0 ; : 165.2 ±81.3 32.0-480.0
Absolute lym phoctye 
count (x 1071) 75 100.0 " 115.8 ±122.2 11.6—648.0
10-29 10 13.3 18.5 ±6.4 11.6-28.5
30-49 11 ‘ ■ 14.7 40.5 ± 5.4 30.1-46.9
50-100 26 - 34.7 ■ ■ ‘ 67.7 ±11.9 52.0-93.7
Over 100 28 . 37.3 ' 224.7 ± 143.1 101.9-648.0
Hb (g/dl):
< 1 0 ............................. 44 58.6 ' 7.8 ±1 .5  ■ ' 3.3-9.9
10 to 12 17. 22.7 10.8 ±0.5 10.0- 12.0
Over 12 14 . '18.7 13.2 ± 1.0 12.1-15.2 ■
Platelet count - -
< 100- 17 . 22.7 ' 72.6 ± 20.2 32-98
100 to 150 20 ' ~ ; 26,7 130.8 ± 15.6 100-150
Over 150 38 ■ 50.6 -■ 224.7 ± 68.6 152-480
Haematological findings : Haematological features at 
diagnosis are shown in Table IIL There was no statistically 
significant difference in the haematological values between 
the Zimbabwean and Malawian groups (p>0.05). The 
overall absolute lymphocyte count ranged from 11.6 to 
648.0 x l0 9/l with a mean ± s.d. of 115.8 ± 122.2 x 1071. 
Seventy two percent had a lymphocyte count equal to or 
greater than 50 x 1071 and in 28% the lymphocyte count 
was between 10 to 49 x 1071. The overall haemoglobin 
(Hb) level showed a mean ± s.d. of 9.5 ± 2.5 g/dl with a 
range of 3.3 to 15.2 g/dl. Of the patients 58.6% had an Hb 
of less than lO.Og/dl. The platelet count ranged from 32 to 
480 x 1071 with a mean ± s.d platelet count of 165.2 ± 81.3 
x 1071 and thrombocytopenia (platelet count <100 x 1071) 
was found in 17 (22.7%) patients with a mean ± s.d platelet' 
count of 72.6 ± 20.2 x 1071; range 32 to 98 x 1071. 
Immunophenotyping revealed that all the 19 (25.3%) 
patients were of the B-CLL type. Fifty six (74.7%) patients 
were not typed due to lack of reagents. The antiglobulin 
(Coomb’s) test performed in 36 patients was positive in 
five(13.9%) patients but none of these had evidence of auto 
immune haemolytic anaemia. Serum protein electrophoresis 
performed in 24 patients showed depressed gamma 
globulins in eight (33.3%) patients.
Table IV: Rai clinical stages in 75 CLL patients.
Stage No.
\
%
0 ' A 9.3
1 2 2.7
11 7 9.3
111 42 56.0
IV 17 22.7
Total 75 100.0
Table IV shows the clinical stages of CLL patients at 
diagnosis according to Rai; et al:10' The majority (78l7%) 
presented with stages III andTV diseaseJStages 0 ,1 and II 
accounted for 9.3%, 2!7% and 9.3% respectively. ■" 
Therapy-, response and outcome: Thirty two (42.7%) 
patients were treated with chemotherapy that was available 
at the time of diagnosis. Seventeen received chlorambucil 
and 15 cyclophosphamide with or without prednisolone. 
Chlorambucil produced complete of partial remissions in 
28.6% and 57.1% respectively and,in 14.3% there was no 
remission. Cyclophosphamide produced complete or partial 
responses in 23.1% and 61.5%.respectively. No response 
was seen in 15.4%. Three patients in the chlorambucil 
group and two, in the cyclophosphamide group were/not 
evaluated as they absconded soon after therapy was started. 
At the time of this presentation, of the remaining evaluable 
27 patients in the group treated with chemotherapy,. six 
patients are.still alive and on follow,up with a mean.±'S.d. 
survival duration of 39.9 ± 24.4 months; median.41 months 
and range eight to 76 months since diagnosis^ . .. , -
Five patients were lost to follow up after a follow up 
period of a,mean ± s.d. of 28.6 ± 18.8 months; median 27 
months, range seven fo^57:months from the time, of 
diagnosis. Sixteen are known to have died and the durationX 
of survival for. this group was a mean.± s.d, of 25.7 ± 19.1 
months; median 19.5 months and range five to 60 months 
after diagnosis. The causes of death were: septicaemia in 
six, pneumonia, in four, pulmonary tuberculosis in. three 
and unknown causes in three. Forty three (57.3%),p.atients 
were not treated due to lack of cytotoxic drugs. Of these 
seven had early disease, 30 were lost to follow up and are 
presumed dead, four died shortly after the diagnosis Of 
CLL was made but post mortems-were refused and two 
refused therapy on religious grounds,
Discussion
Chronic lymphocytic leukaemia (CLL) is the most common 
form of leukaemia in North America and Europe accounting 
for one third of all leukaemias in humans. It is extremely 
rare in Orientals and their descendants who migrated, to 
America and Europe.2'3 In the western countries, the disease 
typically occurs in older p atients, with the highest incidence 
being in those aged 50 to 60 years. It affects men twice as 
often as women.3 However, in sub-Saharan Africa CLL 
rates range from .12 to 40%. 4'7-12 It has been reported to 
occur from the teens to the elderly and the overall M:F ratio 
is 1:1 as was found in this study.4 • • •
But there-is a bimodal distribution; about half of the 
patients being aged 45 years or less and in them the M:F 
ratio is 1:2. Over the age of 45 the M:F ratio is 2:1 as in 
developed western countries.4
In this study in 16 (21.3%) patients CLL occurred below ' 
the age of 50 years and of those 16 patients, 10 (62.5%)( 
were women of a relatively younger age just as it was found 
by Fleming, et al. in neighbouring Zambia5 and Kulkarnj. 
in Nigeria.12
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. .It has been postulated that CLL occurring in younger 
adults in Africa is a consequence of recurrent malaria and 
other infections, resulting in a polyclonal B-cell 
proliferation which in an extreme form is hyper reactive 
malarial splenomegaly (HMS).5 B-cell proliferation is 
greatest with the more frequent exposure to infection 
associated with rural poverty and with recurrent depression 
of cell mediated immunity during the pregnancy of the 
grand multipaxae.4’5 .
A second event that has been hypothesized as leading to 
transformation to a monoclonal B-cell proliferation could 
be an infection by an unidentified virus whose transmission 
is. more frequent in impoverished rural communities and 
whose impact is enhanced by the depression of immunity 
by malaria and pregnancy.4'5
The main clinical presentation in this series were 
symptoms attributable to splenomegaly and hepatomegaly 
that caused the patients to seek medical attention, unlike in 
the western hemisphere where lymphadenopathy is the 
dominant presenting clinical feature.2'3-9 Splenomegaly 
and hepatomegaly accounted for 68% and 37.3% 
respectively, figures which are comparable to the 
Ethiopian13 figures of 55.9% and 32.4%, unlike in Kenyans 
where figures of 80.9% and 76.5% werefound.14Significant 
pallor, which is rare in Caucasians,2 was noted in 34.7%, 
but Shamebo, et al.13 and Oloo, et al.14 found figures of 
37.3% and 59.5% in their series. In western developed 
nations,2'9 with the use of routine blood testing, the number 
of CLL patients diagnosed incidentally is around 40 to 
60%, unlike in Ethiopians13 and this series where.respective 
figures of 4.9% and 12.0% accounted fo;: incidental 
diagnoses of CLL. In this study, only seven (9.3%) patients r 
were in stage 0. Stages I and II, III and IV accounted for 
12.0% and 78.7% respectively in contrast to the study by 
Gale, et al.'5 who reported 25% in stage 0, 50% in stage I 
and II and 25% in stage III and IV. The findings in this 
study, therefore, show that most of our patients seek;,, 
medical attention in late stages of the disease, as in the . 
Ethiopian13 and Kenyan14, studies.
There is controversy as to at what degree of lymphocytosis 
should the diagnosis of CLL be considered. A level above 
five to 10 x 109/1 has been established in most commonly 
accepted staging systems.9 "
■ In our patients the overall absolute lymphocyte count 
was mean ± s.d. of 115.8 ± 122.2 x 109/1; range 11.6 to 
648.0 x 109/1; and in 72% of the patients the absolute 
lymphocyte count was above 50xl09/l; a figure which is in 
agreement with a figure of 70% reported in Kenyans.14 
Platelet counts of 100 to 150 x 109/1 and <100 x 109/1 were 
recorded in 26.7% and 22.7% respectively. Two patients ■ 
with platelet counts of 32.0 x 109/1 and 48.0. x 109/1 
presented with bleeding tendencies especially from mucus 
membranes. The overall mean ±s.d. haemoglobin was 9.5 
± 2.5 g/dl; range 3.3 to 15.2g/dl with 81.3% having less 
than 12.0g/dl and 58.6% less than lO.Og/dl. In the 
Ethiopian13 study mean haemoglobin was found to. be 
10.77g/dl with 62.7% having less than 12.0g/dl and 37.3%
less than lO.Og/dl; whereas in Kenyans,14 anaemia was 
even more marked; Hb less than 8.0g/dl was reported in 
66.7%. - ■. .
In western countries, patients rarely present with pallor 
or other features of anaemia.2 About 20% of CLL patients 
have a positive Coombs’ test at some time in their illness 
but only about 8% develop an auto-immune haemolytic 
anaemia.15 In this series Coombs test, performed only in 36 
(48%) patients, was positive in five (13.9%) patients but 
none of the patients had evidence of auto-immune 
haemolytic anaemia. It is also interesting to note that 
immunophenotyping done in 19 (25.3%) patients revealed 
that all of them were of the B-CLL origin, which is in total 
agreement with the western pattern.2,3 In the western 
hem isphere responses to ch loram bucil ■ and 
cyclophosphamide with or without prednisolone have 
ranged from 38% to 100% but the interpretation of these 
data is difficult because of the lack of homogeneity in the 
groups of patients studied.1'3
In our patients that could be evaluated for outcome of 
treatment, overall responses of 85.7% and 84.6% which 
were found for chlorambucil and cyclophosphamide are 
similar to those reported in the literature.1'3'11-16 However, 
most patients in tropical Africa do not benefit from the 
advances in leukaemia therapy and other malignancies in 
general. Besides, there are other constraints which are 
related to CLL management viz: limited laboratory 
diagnostic facilities like immunophenotyping, lack of 
chemotherapy agents, lack of support services, poor patient 
compliance and a high default rate. Consequently, lack of 
■ - accurate diagnosis results in inappropriate staging and 
therapy. Therefore, establishment of multicentre studies 
and a major investment into haemato-oncology in tropical 
Africa twinning with centres in industrialized countries are 
required and should be followed by commensurate 
humanitarian benefit.
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